MX2022016458A - Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75). - Google Patents

Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75).

Info

Publication number
MX2022016458A
MX2022016458A MX2022016458A MX2022016458A MX2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A
Authority
MX
Mexico
Prior art keywords
obesity
gpr75
coupled receptor
protein coupled
inhibitors
Prior art date
Application number
MX2022016458A
Other languages
English (en)
Inventor
Aris Baras
Manuel Allen Revez Ferreira
Luca Andrea Lotta
Parsa Akbari
Olukayode Sosina
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022016458A publication Critical patent/MX2022016458A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La presente descripción proporciona métodos para tratar sujetos que tienen obesidad, métodos para identificar sujetos que tienen un mayor riesgo de desarrollar obesidad, métodos para detectar moléculas de ácido nucleico variantes del receptor 75 acoplado a proteínas G humanas y polipéptidos variantes, y moléculas de ácido nucleico variantes de GPR75 y polipéptidos variantes.
MX2022016458A 2020-06-22 2021-06-21 Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75). MX2022016458A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063042327P 2020-06-22 2020-06-22
US202063066185P 2020-08-15 2020-08-15
US202063075858P 2020-09-09 2020-09-09
US202063089625P 2020-10-09 2020-10-09
US202063104613P 2020-10-23 2020-10-23
US202163142632P 2021-01-28 2021-01-28
US202163159017P 2021-03-10 2021-03-10
US202163210287P 2021-06-14 2021-06-14
US202163211061P 2021-06-16 2021-06-16
PCT/US2021/038260 WO2021262601A1 (en) 2020-06-22 2021-06-21 Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors

Publications (1)

Publication Number Publication Date
MX2022016458A true MX2022016458A (es) 2023-04-05

Family

ID=76943116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016458A MX2022016458A (es) 2020-06-22 2021-06-21 Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75).

Country Status (10)

Country Link
US (2) US11359246B2 (es)
EP (1) EP4168548A1 (es)
JP (1) JP2023531935A (es)
KR (1) KR20230041709A (es)
CN (1) CN116249787A (es)
AU (1) AU2021296270A1 (es)
CA (1) CA3186576A1 (es)
IL (1) IL298930A (es)
MX (1) MX2022016458A (es)
WO (1) WO2021262601A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021296270A1 (en) * 2020-06-22 2023-02-02 Regeneron Pharmaceuticals, Inc. Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
WO2023250130A2 (en) * 2022-06-24 2023-12-28 The Regents Of The University Of California Compositions and methods involving adgrg6

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040790A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
US20080108145A1 (en) 2006-11-07 2008-05-08 Stephanie Chissoe Genes associated with osteoarthritis
US20080108080A1 (en) * 2006-11-07 2008-05-08 Stephanie Chissoe Genes associated with obesity
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US8185323B1 (en) 2008-01-06 2012-05-22 Degen Zhuo Method of identifying exons and introns and diagnostic uses thereof
US10446261B1 (en) 2008-01-06 2019-10-15 Biotailor, Inc. System and method for analyzing splicing codes of spliceosomal introns
US20110177964A1 (en) 2009-12-03 2011-07-21 The Trustees Of Princeton University Chemosensory arrays
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
US20140377278A1 (en) 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
WO2015017656A1 (en) 2013-07-31 2015-02-05 The Regents Of The University Of California Methods of diagnosis and treatment for pulmonary arterial hypertension
WO2017004153A1 (en) 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
US20230000912A1 (en) 2016-01-25 2023-01-05 The Broad Institute, Inc. Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof
WO2017156164A1 (en) 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use
EP3439688A4 (en) 2016-04-04 2020-05-27 The Regents of the University of California COMPOSITIONS AND METHODS IN CONNECTION WITH POLYCYTOTOXIC T CELLS
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
US11878060B2 (en) 2016-08-07 2024-01-23 Novartis Ag mRNA-mediated immunization methods
WO2019006246A1 (en) 2017-06-30 2019-01-03 The Rockefeller University N-ACYL AMIDES DERIVED FROM THE HUMAN MICROBIOTE FOR THE TREATMENT OF A HUMAN DISEASE
US20200207836A1 (en) 2017-08-22 2020-07-02 Monash University Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020118363A1 (en) 2018-12-10 2020-06-18 Monash University Screening assays, modulators and modulation of intracellular signalling mediated by immunoglobulin superfamily cell adhesion molecules
WO2020247220A1 (en) 2019-06-03 2020-12-10 University Of Florida Research Foundation, Inc. Compositions and methods for predicting susceptibility of cancers to synthetic-lethal therapies
AU2021296270A1 (en) * 2020-06-22 2023-02-02 Regeneron Pharmaceuticals, Inc. Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

Also Published As

Publication number Publication date
AU2021296270A1 (en) 2023-02-02
US20220042101A1 (en) 2022-02-10
CN116249787A (zh) 2023-06-09
US11359246B2 (en) 2022-06-14
WO2021262601A1 (en) 2021-12-30
IL298930A (en) 2023-02-01
JP2023531935A (ja) 2023-07-26
US20220411870A1 (en) 2022-12-29
KR20230041709A (ko) 2023-03-24
CA3186576A1 (en) 2021-12-30
EP4168548A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
MX2022016458A (es) Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75).
MX2021008797A (es) Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
BRPI0720035A2 (pt) métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
Salpeter et al. A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
BR112017025773A2 (pt) métodos de diagnóstico e tratamento de câncer
ATE516748T1 (de) Gerät zur behandlung von bewegungsstörungen
JP2017524130A5 (es)
Sebastian et al. A novel in vitro assay for electrophysiological research on human skin fibroblasts: degenerate electrical waves downregulate collagen I expression in keloid fibroblasts
MX2023007012A (es) Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe).
DE60025368D1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
BRPI0912927A2 (pt) "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"
MX2020000186A (es) Ensayos para evaluar los niveles de anticuerpos neutralizantes en sujetos tratados con un fármaco biológico y usos de los mismos en medicina personalizada.
BR112017022320A2 (pt) métodos para tratamento de câncer de pulmão
MX2021009983A (es) Variantes del componente 1 de canales ionicos mecanosensibles de tipo piezo (piezo1) y usos de estas.
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
DE60239012D1 (de) Verfahren zum identifizieren von mustern in biologischen systemen und deren anwendungen
WO2008074029A3 (en) Protein profile for osteoarthritis
MX2021011015A (es) Tratamiento de la hiperglucemia con inhibidores del miembro 5 de la familia 39 de los transportadores de solutos (slc39a5).
MX2021007938A (es) Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).
MX2020009363A (es) Un método para detectar magea4.
EA202192289A1 (ru) Способы мечения эукариотных клеток многоклеточного организма, а также лечения и/или диагностики рака с использованием модифицированных моносахаридных соединений
Ru et al. Stimulus intensity-dependent recruitment of NaV1 subunits in action potential initiation in nerve terminals of vagal C-fibers innervating the esophagus
MX2023001914A (es) Tratamiento de la obesidad en sujetos que tienen variantes de moleculas de acido nucleico que codifican el receptor de calcitonina (calcr).